AZD5069 Clinical Trials

Size	Price	Qty
5mg	USD 147
25mg	USD 457

Clinical Trials

Numerous early-phase clinical trials, encompassing Phase 1, Phase 2, and combined Phase 1/2 studies, have evaluated the CXCR2 antagonist AZD5069 across respiratory inflammatory diseases and oncology indications. These investigations evaluated the compound in chronic obstructive pulmonary disease, persistent asthma, bronchiectasis, metastatic castration-resistant prostate cancer, and advanced solid tumors, including head and neck squamous cell carcinoma. Sponsored by pharmaceutical entities and research institutions, these completed and terminated studies reflect a clinical development strategy aimed at dampening pathological immune responses.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03177187	TERMINATED	Metastatic Castration Resistant Prostate Cancer	Institute of Cancer Research, United Kingdom	2017-11-13	PHASE1; PHASE2
NCT02499328	COMPLETED	Advanced Solid Tumors & Metastatic Squamous Cell Carcinoma of the Head and Neck	AstraZeneca	2015-08-06	PHASE1; PHASE2
NCT02583477	COMPLETED	Metastatic Pancreatic Ductal Adenocarcinoma	AstraZeneca	2016-03-25	PHASE1; PHASE2
NCT03177187	Terminated	Metastatic Castration Resistant Prostate Cancer	Institute of Cancer Research United Kingdom\|Astellas Pharma Inc\|AstraZeneca\|Prostate Cancer UK	2017-11-13	Phase 1\|Phase 2
NCT01704495	COMPLETED	Asthma	AstraZeneca	2012-11	PHASE2
NCT01890148	COMPLETED	Asthma	AstraZeneca	2014-03	PHASE1
NCT01962935	COMPLETED	Chronic Obstructive Pulmonary Disease (COPD).	AstraZeneca	2013-11	PHASE1
NCT01989520	COMPLETED	Uncontrolled and Persistent Asthma	AstraZeneca	2014-01	PHASE1
NCT01962935	Completed	Chronic Obstructive Pulmonary Disease (COPD).	AstraZeneca	2013-11	Phase 1
NCT01735240	COMPLETED	Asthma,; Pharmacokinetics,; Cmax,; Tmax,; λz,; AUC,; Ketoconazole,; Metabolite	AstraZeneca	2012-12	PHASE1
NCT01735240	Completed	Asthma\|Pharmacokinetics\|Cmax\|Tmax\|λz\|AUC\|Ketoconazole\|Metabolite	AstraZeneca	2012-12	Phase 1
NCT01480739	COMPLETED	Chemokine Receptor 2 (CXCR2) Antagonist	AstraZeneca	2011-12	PHASE1
NCT01255592	COMPLETED	Bronchiectasis; Lung Disease; Respiratory Diseases	AstraZeneca	2011-02	PHASE2
NCT01332903	COMPLETED	Healthy	AstraZeneca	2011-05	PHASE1
NCT01233232	COMPLETED	Scientific Terminology Chronic Obstructive Pulmonary Disease (COPD); Laymen Terminology Chronic Bronchitis and Emphysema	AstraZeneca	2010-11	PHASE2
NCT01100047	COMPLETED	Healthy	AstraZeneca	2010-05	PHASE1
NCT01083238	COMPLETED	Chronic Obstructive Pulmonary Disease	AstraZeneca	2010-02	PHASE1
NCT01051505	COMPLETED	Healthy	AstraZeneca	2010-01	PHASE1
NCT00953888	COMPLETED	Healthy	AstraZeneca	2009-07	PHASE1

(data from https://clinicaltrials.gov, updated on 2024-09-26)

Check the AZD5069 product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

AZD5069 acts as a potent small-molecule antagonist of the chemokine receptor CXCR2, potently inhibiting CXCL8 binding and suppressing downstream intracellular signaling cascades essential for neutrophil activation and migration. By disrupting CXCR2-mediated cell recruitment and proinflammatory pathways, this targeted inhibition reduces pathological tissue inflammation and alters the tumor microenvironment in clinical conditions such as chronic obstructive pulmonary disease, asthma, and metastatic prostate cancer.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).